Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.

Mai E, Zheng Z, Chen Y, Peng J, Severin C, Filvaroff E, Romero M, Mallet W, Kaur S, Gelzleichter T, Nijem I, Merchant M, Young JC.

Mol Cancer Ther. 2014 Feb;13(2):540-52. doi: 10.1158/1535-7163.MCT-13-0494. Epub 2013 Nov 20.

2.

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.

Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, Santell L, Zhang YW, Su Y, Kaufman DW, Billeci KL, Mai E, Moffat B, Lim A, Duenas ET, Phillips HS, Xiang H, Young JC, Vande Woude GF, Dennis MS, Reilly DE, Schwall RH, Starovasnik MA, Lazarus RA, Yansura DG.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. doi: 10.1073/pnas.1302725110. Epub 2013 Jul 23.

3.

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.

Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, Roux B, Lamballe F, Ginestier C, Charafe-Jauffret E, Maina F, Brouckaert P, Saunders M, Thibault A, Dreier T, de Haard H, Michieli P.

Cancer Res. 2015 Aug 15;75(16):3373-83. doi: 10.1158/0008-5472.CAN-15-0356. Epub 2015 Jul 3.

4.

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.

Liu L, Zeng W, Wortinger MA, Yan SB, Cornwell P, Peek VL, Stephens JR, Tetreault JW, Xia J, Manro JR, Credille KM, Ballard DW, Brown-Augsburger P, Wacheck V, Chow CK, Huang L, Wang Y, Denning I, Davies J, Tang Y, Vaillancourt P, Lu J.

Clin Cancer Res. 2014 Dec 1;20(23):6059-70. doi: 10.1158/1078-0432.CCR-14-0543. Epub 2014 Sep 17.

5.

HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.

Penuel E, Li C, Parab V, Burton L, Cowan KJ, Merchant M, Yauch RL, Patel P, Peterson A, Hampton GM, Lackner MR, Hegde PS.

Mol Cancer Ther. 2013 Jun;12(6):1122-30. doi: 10.1158/1535-7163.MCT-13-0015. Epub 2013 Mar 27.

6.

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.

Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, Laterra J.

Clin Cancer Res. 2006 Feb 15;12(4):1292-8.

7.

Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development.

Xiang H, Bender BC, Reyes AE 2nd, Merchant M, Jumbe NL, Romero M, Davancaze T, Nijem I, Mai E, Young J, Peterson A, Damico-Beyer LA.

Clin Cancer Res. 2013 Sep 15;19(18):5068-78. doi: 10.1158/1078-0432.CCR-13-0260. Epub 2013 Jul 26.

8.

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.

Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R.

Cancer Res. 2006 Feb 1;66(3):1721-9. Erratum in: Cancer Res. 2006 Jun 1;66(11):5976.

9.

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.

Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, Furge K, Sun J, Rex K, Osgood T, Coxon A, Burgess TL, Vande Woude GF.

Mol Cancer Ther. 2009 Oct;8(10):2803-10. doi: 10.1158/1535-7163.MCT-09-0125.

10.

A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.

Yu Y, Chen Y, Ding G, Wang M, Wu H, Xu L, Rui X, Zhang Z.

Biochem Biophys Res Commun. 2015 Aug 14;464(1):154-60. doi: 10.1016/j.bbrc.2015.06.107. Epub 2015 Jun 18.

PMID:
26093299
11.

Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.

van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, Lam A, Ji M, Hoey TC, Sato AK.

Neoplasia. 2009 Apr;11(4):355-64.

12.

Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met-expressing tumors.

Francone TD, Landmann RG, Chen CT, Sun MY, Kuntz EJ, Zeng Z, Dematteo RP, Paty PB, Weiser MR.

Mol Cancer Ther. 2007 Apr;6(4):1460-6.

13.

Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474.

Klotz M, Schmid E, Steiner-Hahn K, Rose T, Laube J, Roese L, Henderson D, Krahn T, von Ahsen O.

Biomarkers. 2012 Jun;17(4):325-35. doi: 10.3109/1354750X.2012.670865. Epub 2012 Mar 28.

PMID:
22452362
14.

Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.

Coxon A, Rex K, Meyer S, Sun J, Sun J, Chen Q, Radinsky R, Kendall R, Burgess TL.

Mol Cancer Ther. 2009 May;8(5):1119-25. doi: 10.1158/1535-7163.MCT-08-1032. Epub 2009 May 12.

15.

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.

Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya KS, Oleksijew A, Boghaert E, Song M, Sokolova I, Pestova E, Anderson M, Pappano WN, Ansell P, Bhathena A, Naumovski L, Corvaia N, Reilly EB.

BMC Cancer. 2016 Feb 16;16:105. doi: 10.1186/s12885-016-2138-z.

16.

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody.

Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De Santis R, Galluzzo M, Carminati P, Comoglio PM, Michieli P, Vigna E.

J Biol Chem. 2010 Nov 12;285(46):36149-57. doi: 10.1074/jbc.M110.134031. Epub 2010 Sep 10.

17.

Self-control of HGF regulation on human trophoblast cell invasion via enhancing c-Met receptor shedding by ADAM10 and ADAM17.

Yang Y, Wang Y, Zeng X, Ma XJ, Zhao Y, Qiao J, Cao B, Li YX, Ji L, Wang YL.

J Clin Endocrinol Metab. 2012 Aug;97(8):E1390-401. doi: 10.1210/jc.2012-1150. Epub 2012 Jun 11.

PMID:
22689693
18.

HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop.

Syed ZA, Yin W, Hughes K, Gill JN, Shi R, Clifford JL.

BMC Cancer. 2011 May 19;11:180. doi: 10.1186/1471-2407-11-180.

19.

Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.

Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P.

J Nucl Med. 2012 Oct;53(10):1592-600. doi: 10.2967/jnumed.111.102293. Epub 2012 Aug 23.

20.

Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.

Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S.

J Clin Pharmacol. 2013 Nov;53(11):1103-11. doi: 10.1002/jcph.148. Epub 2013 Aug 7.

PMID:
23922054

Supplemental Content

Support Center